Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose-lowering agent: An analysis from VERTIS CV Article Early Access

Industry Collaboration International Collaboration

cited authors

  • Dagogo-Jack, Samuel; Cannon, Christopher P.; Cherney, David Z., I; Cosentino, Francesco; Liu, Jie; Pong, Annpey; Gantz, Ira; Frederich, Robert; Mancuso, James P.; Pratley, Richard E.

authors

Publication Date

  • March 29, 2022

webpage

published in

category

keywords

  • SGLT2 inhibitor
  • cardiovascular disease
  • type 2 diabetes